Loading
A phase 2 trial of IBI363, Pembrolizumab in melanoma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy is a phase 2 interventional study registered as NCT06797297 by Innovent Biologics (Suzhou) Co. Ltd., with 180 participants planned, started 2025-02-24 and due to reach its primary completion in 2026-03-31. Interventions recorded: IBI363, Pembrolizumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Shares IBI363, Innovent Biologics, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares IBI363, Innovent Biologics, Melanoma.
Shares IBI363, Innovent Biologics, Pembrolizumab, Immune checkpoint inhibitors.
Shares Acral melanoma, Mucosal melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Acral melanoma, Mucosal melanoma, Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares IBI363, Innovent Biologics.